EGFR and neoplasm: The lack of pathways blockade in TCG2 model despite the EGFR dephosphorylation corroborates recent clinical data demonstrating that gefitinib has reached the tumor, efficiently dephosphorylated the target, but was not able to control the pathways activity [28].